Melatonin and non-small cell lung cancer: new insights into signaling pathways

Area of Science:

• Oncology
• Molecular Biology
• Endocrinology

Background:

• Non-small-cell lung cancer (NSCLC) presents a significant global health challenge with poor prognosis due to late diagnosis and limited treatment options.
• Current standard treatments like chemotherapy and radiotherapy for NSCLC are often insufficient and associated with severe side effects.
• There is a critical need for novel therapeutic strategies to improve survival rates and quality of life for NSCLC patients.

Purpose of the Study:

• To review the current data on melatonin's role in non-small-cell lung cancer (NSCLC).
• To explore the molecular mechanisms and signaling pathways through which melatonin exerts its effects on NSCLC.
• To evaluate the potential of melatonin as an adjunct therapy for NSCLC.

Main Methods:

• Literature review of studies investigating melatonin and NSCLC.
• Analysis of molecular mechanisms including apoptosis induction, cell proliferation restraint, and anti-inflammatory effects.
• Examination of signaling pathways involved in melatonin's action on cancer cells.

Main Results:

• Melatonin demonstrates potential in preventing NSCLC metastasis by inducing apoptosis and restraining cell proliferation.
• Melatonin exhibits oncostatic, pro-oxidant, and anti-inflammatory properties that inhibit tumor progression.
• Combined treatment with melatonin and chemotherapy may yield synergistic effects, potentially improving patient outcomes.

Conclusions:

• Melatonin shows promise as a therapeutic agent for non-small-cell lung cancer (NSCLC).
• Its multifaceted actions, including anti-metastatic and anti-proliferative effects, warrant further investigation.
• Melatonin supplementation could be a valuable addition to conventional NSCLC treatments, enhancing efficacy and patient quality of life.